Chronic Pulmonary Hypertension Market

DelveInsight’s ‘Chronic Pulmonary Hypertension Market Insights, Epidemiology and Market Forecast—2032’ report deliver an in-depth understanding of the Chronic Pulmonary Hypertension, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Chronic Pulmonary Hypertension market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Chronic Pulmonary Hypertension symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Chronic Pulmonary Hypertension symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Chronic Pulmonary Hypertension Understanding and Treatment Algorithm

Chronic Pulmonary Hypertension Overview

Pulmonary hypertension encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance. Pulmonary hypertension is a progressive disease with treatment focused on management of symptoms and treatment of underlying diseases.

 

Some common underlying causes of pulmonary hypertension include high blood pressure in the lungs’ arteries due to some types of congenital heart disease, connective tissue disease, coronary artery disease, high blood pressure, liver disease (cirrhosis), blood clots to the lungs, and chronic lung diseases like emphysema. Genetics also play a role.

 

Pulmonary hypertension can happen in association with many other diseases, such as lung disease and heart disease. Heart failure is common in pulmonary hypertension.

 

The symptoms of pulmonary hypertension during the initial stage of the disease are common to many other medical conditions (e.g., difficulty breathing, fatigue). This often results in a delayed diagnosis until more severe symptoms arise, such as dizziness, chest pain, ankle swelling, or feeling the heart race or pound (palpitations).

 

Diagnosis of PH is commonly delayed as the presenting symptoms overlap other disease processes. Other conditions to be considered in the differential diagnosis include, but are not limited to, congestive heart failure, coronary artery disease, pulmonary fibrosis, chronic obstructive pulmonary disease, valvular heart disease, hypothyroidism, and pulmonary embolism.

 

There is no cure for pulmonary hypertension. However, there are many different types of treatments, including, Inhaled medicine, Medicine given through the veins under the skin, Medicine to reduce swelling in the feet (diuretics), Oxygen therapy.

 

Currently, even with PAH-specific drug treatment, prognosis for PAH and CTEPH patients remains poor, with mean five-year survival rates of 57%-59% and 53%-69% for PAH and inoperable CTEPH, respectively. Therefore, more insight into the pathogenesis of PAH and CTEPH is highly needed, so that new therapeutic strategies can be developed. 

 

Recent studies have shown increased presence and activation of innate and adaptive immune cells in both PAH and CTEPH patients. Moreover, extensive biomarker research revealed that many inflammatory and immune markers correlate with the hemodynamics and/or prognosis of PAH and CTEPH patients. 

 

Chronic Pulmonary Hypertension Diagnosis and Treatment 

It covers the details of conventional and current medical therapies and diagnosis available in the Chronic Pulmonary Hypertension market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, the Europe, and Japan. 

 

The DelveInsight Chronic Pulmonary Hypertension market report gives a thorough understanding of Chronic Pulmonary Hypertension symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Chronic Pulmonary Hypertension algorithms and treatment guidelines in the US, the Europe, and Japan. 

Chronic Pulmonary Hypertension Epidemiology 

The epidemiology division’s Chronic Pulmonary Hypertension symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Pulmonary Hypertension epidemiology segmented as the Total Prevalent cases of Chronic Pulmonary Hypertension, Group-specific Prevalence of Chronic Pulmonary Hypertension, Gender-specific prevalent cases of Chronic Pulmonary Hypertension, and Age-specific prevalent cases of Chronic Pulmonary Hypertension. The report includes the Chronic Pulmonary Hypertension scenario in the 7MM, covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032. 

Country Wise-Chronic Pulmonary Hypertension Epidemiology 

The epidemiology segment also provides the Chronic Pulmonary Hypertension epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

 

The total 7MM prevalent population of Chronic Pulmonary Hypertension were 42,184,011 cases in 2021.

Chronic Pulmonary Hypertension Drug Chapters 

The drug chapter segment of the Chronic Pulmonary Hypertension report encloses the detailed analysis of Chronic Pulmonary Hypertension marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Chronic Pulmonary Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Chronic Pulmonary Hypertension Emerging Drugs 

 

CS1 (Cereno Scientific AB)

The drug candidate CS1 is a new advanced reformulation of valproic acid (VPA) and acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic, and pressure-relieving properties. CS1 is being developed as a treatment for the rare disease pulmonary arterial hypertension (PAH) to offer patients a better, disease-modifying drug. CS1’s epigenetic mechanism is expressed through HDAC (histone deacetylase) inhibition and brings a novel treatment approach to cardiovascular disease

Products detail in the report…

Chronic Pulmonary Hypertension Market Outlook

The Chronic Pulmonary Hypertension market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Chronic Pulmonary Hypertension market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology. 

 

This segment gives a thorough detail of Chronic Pulmonary Hypertension market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

 

According to DelveInsight, Chronic Pulmonary Hypertension market in 7MM is expected to change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Chronic Pulmonary Hypertension market in 7MM. The market size of Chronic Pulmonary Hypertension in the seven major markets was found to be USD 94,693.26 million in 2021. 

 

The United States Market Outlook

This section provides a total of Chronic Pulmonary Hypertension market size and market size by therapies in the United States. 

 

The United States accounts for higher Chronic Pulmonary Hypertension market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. 

 

The EU-5 Countries: Market Outlook

The total Chronic Pulmonary Hypertension market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook 

The total Chronic Pulmonary Hypertension market size and market size by therapies in Japan are also mentioned. 

Chronic Pulmonary Hypertension Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Chronic Pulmonary Hypertension market uptake by drugs, patient uptake by therapies, and drug sales. 

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Chronic Pulmonary Hypertension Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Chronic Pulmonary Hypertension key players involved in developing targeted therapeutics. 

 

Major players Supernitro (PDNO) (Attgeno AB), CS1, and others are being assessed as potential therapies to be available in the market in the coming future.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Chronic Pulmonary Hypertension emerging therapies.

KOL Views 

To keep up with current market trends, we take KOLs and SME’s opinion working on Chronic Pulmonary Hypertension domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Chronic Pulmonary Hypertension market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs. 

Competitive Intelligence Analysis 

We perform a Competitive and Market Intelligence analysis of the Chronic Pulmonary Hypertension Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Chronic Pulmonary Hypertension explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Chronic Pulmonary Hypertension epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Pulmonary Hypertension provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chronic Pulmonary Hypertension market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Chronic Pulmonary Hypertension market

Report Highlights

  • In the coming years, Chronic Pulmonary Hypertension market is set to change due to the rising awareness of the disease, resistant to the current antibiotic regime, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pulmonary Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Chronic Pulmonary Hypertension. The launch of emerging therapies will significantly impact the Chronic Pulmonary Hypertension market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Pulmonary Hypertension
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Pulmonary Hypertension Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic Pulmonary Hypertension Pipeline Analysis
  • Chronic Pulmonary Hypertension Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Pulmonary Hypertension Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Chronic Pulmonary Hypertension Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake

Chronic Pulmonary Hypertension Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Chronic Pulmonary Hypertension Market share (%) distribution in 2022, and how would it look in 2032?
  • What would be the Chronic Pulmonary Hypertension total market Size as well as market Size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the market’s key findings across 7MM, and which country will have the largest Chronic Pulmonary Hypertension market Size during the forecast period (2022–2032)?
  • At what CAGR, the Chronic Pulmonary Hypertension market is expected to grow by 7MM during the forecast period (2022–2032)?
  • What would be the Chronic Pulmonary Hypertension market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Chronic Pulmonary Hypertension market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Chronic Pulmonary Hypertension?
  • What is the historical Chronic Pulmonary Hypertension patient pool in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Chronic Pulmonary Hypertension in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Chronic Pulmonary Hypertension?
  • Out of all 7MM countries, which country would have the highest prevalent Chronic Pulmonary Hypertension population during the forecast period (2022–2032)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Chronic Pulmonary Hypertension?
  • What are the current treatment guidelines for treating Chronic Pulmonary Hypertension in the US, the Europe, and Japan?
  • What are the Chronic Pulmonary Hypertension marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Chronic Pulmonary Hypertension?
  • How many therapies are developed by each company for the treatment of Chronic Pulmonary Hypertension?
  • How many emerging therapies are in the mid-stage and late development stages to treat Chronic Pulmonary Hypertension?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Pulmonary Hypertension therapies? 
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Chronic Pulmonary Hypertension and their status?
  • What are the key designations that have been granted for the emerging therapies for Chronic Pulmonary Hypertension?
  • What are the global historical and forecasted markets of Chronic Pulmonary Hypertension?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Pulmonary Hypertension market
  • To understand the future market competition in the Chronic Pulmonary Hypertension market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Pulmonary Hypertension in the US, the Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Pulmonary Hypertension market
  • To understand the future market competition in the Chronic Pulmonary Hypertension market

1. Report Introduction

2. Chronic Pulmonary Hypertension Market Overview at a Glance

2.1. Market Share (%) Distribution of Chronic Pulmonary Hypertension in 2019

2.2. Market Share (%) Distribution of Chronic Pulmonary Hypertension in 2032

3. Executive Summary of Chronic Pulmonary Hypertension

4. Disease Background and Overview

4.1. Introduction

4.2. Clinical Classification of Pulmonary Hypertension

4.2.1. GROUP 1: Pulmonary Arterial Hypertension (PAH)

4.2.2. GROUP 2: Pulmonary Hypertension (PH) due to Left Heart Disease

4.2.3. GROUP 3: Pulmonary Hypertension (PH) due to Lung Diseases and/or Hypoxia

4.2.4. GROUP 4: Chronic Thromboembolic PH (CTEPH)

4.2.5. GROUP 5: PH with Unclear Multifactorial Mechanisms

4.3. Etiology of Pulmonary Hypertension

4.4. Causes of Pulmonary Hypertension

4.5. Signs and Symptoms

4.6. Pathogenesis and Pathophysiology of PH

4.7. Diagnosis of PH

4.8. Differential Diagnosis of PH

4.9. Prognosis of PH

5. Management and Treatment

5.1. Treatment of Pulmonary Hypertension

5.1.1. WHO GROUP 1 PH: Pulmonary Arterial Hypertension (PAH)

5.1.2. WHO GROUP 2 PH

5.1.3. WHO GROUP 3 PH

5.1.4. WHO GROUP 4 PH

5.1.5. WHO GROUP 5 PH

5.2. Management of Pulmonary Hypertension

5.2.1. American Guidelines for Diagnosis and Treatment of Pulmonary Hypertension

5.2.2. ESC (European Society of Cardiology) Guidelines for Diagnosis and Treatment of Pulmonary Hypertension

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Total number of Prevalent cases of Chronic Pulmonary Hypertension in the 7MM

6.3. Assumptions and Rationale

6.4. The United States

6.4.1. Total Prevalent cases of Chronic Pulmonary Hypertension in the United States

6.4.2. Group-specific Prevalence of Chronic Pulmonary Hypertension in the United States

6.4.3. Gender-specific prevalent cases of Chronic Pulmonary Hypertension in the United States

6.4.4. Age-specific prevalent cases of Chronic Pulmonary Hypertension in the United States

6.5. The EU5

6.5.1. Total Prevalent cases of Chronic Pulmonary Hypertension in the EU5

6.5.2. Group-specific Prevalence of Chronic Pulmonary Hypertension in the EU5

6.5.3. Gender-specific prevalent cases of Chronic Pulmonary Hypertension in the EU5

6.5.4. Age-specific prevalent cases of Chronic Pulmonary Hypertension in the EU5

6.6. Japan

6.6.1. Total Prevalent cases of Chronic Pulmonary Hypertension in Japan

6.6.2. Group-specific Prevalence of Chronic Pulmonary Hypertension in Japan

6.6.3. Gender-specific prevalent cases of Chronic Pulmonary Hypertension in Japan

6.6.4. Age-specific prevalent cases of Chronic Pulmonary Hypertension in Japan

7. Patient Journey 1

8. Patient Journey 2

9. Marketed Drugs

9.1. Adempas® (Riociguat): Bayer

9.1.1. Drug Description

9.1.2. Other Development Information

9.1.3. Safety and Efficacy

9.1.4. Product Profile

10. Emerging Drugs

10.1. Supernitro (PDNO): Attgeno AB

10.1.1. Drug Descriptions

10.1.2. Other Developmental Activities

10.1.3. Clinical Development

10.1.4. Clinical Trials Information

10.1.5. Product Profile

10.2. CS1: Cereno Scientific AB

10.2.1 Drug Descriptions

10.2.2. Other Developmental Activities

10.2.3. Clinical Development

10.2.4. Clinical Trials Information

10.2.5. Product Profile

10.3. Zamicastat (BIA 5-1058): Bial - Portela C S.A

10.3.1. Drug Descriptions

10.3.2. Other Developmental Activities

10.3.3. Clinical Development

10.3.4. Clinical Trials Information

10.3.5. Product Profile

10.4. YUTREPIA (LIQ861 Inhaled Treprostinil): Liquidia Technologies

10.4.1. Drug Descriptions

10.4.2. Other Developmental Activities

10.4.3. Clinical Development

10.4.4. Clinical Trials Information

10.4.5. Product Profile

10.5. INOpulse® A: Bellerophon Therapeutics

10.5.1. Drug Description

10.5.2. Clinical Development

10.5.3. Clinical Trials Information

10.5.4. Product Profile

10.6. Levosimendan: AbbVie/Tenax Therapeutics

10.6.1. Drug Description

10.6.2. Other Developmental Activities

10.6.3. Clinical Development

10.6.4. Clinical Trials Information

10.6.5. Product Profile

10.7. Treprostinil palmitil: Insmed

10.7.1. Drug Description

10.7.2. Clinical Development

10.7.3. Clinical Trials Information

10.7.4. Product Profile

10.8. Rodatristat Ethyl: Altavant Sciences

10.8.1. Drug Description

10.8.2. Other Development Information

10.8.3. Clinical Development

10.8.4. Clinical Trials Information

10.8.5. Product Profile

11. Generic Therapies

11.1. Endothelin receptor antagonists

11.2. Phosphodiesterase-5 Enzyme Inhibitors

11.3. Prostacyclin Analogue

11.4. Calcium Channel Blockers

11.5. Anticoagulants

11.6. Cardiac Glycosides

12. Chronic Pulmonary Hypertension: Seven Major Market Analysis

12.1. Key Findings

12.2. Market Size of Chronic Pulmonary Hypertension in the 7MM Countries

12.3. Market Size of Chronic Pulmonary Hypertension by Therapies in the 7MM Countries

12.4. 7MM Market Outlook

12.5. The United States Market Size

12.5.1. Total Market Size of Chronic Pulmonary Hypertension in the United States

12.5.2. Market Size by Therapies of Chronic Pulmonary Hypertension in the United States

12.6. The EU-5 Market Size

12.6.1. Total Market size of Chronic Pulmonary Hypertension in the EU5

12.6.2. Market Size by Therapies of Chronic Pulmonary Hypertension in the EU5

12.7. Japan

12.7.1. Total Market Size of Chronic Pulmonary Hypertension in Japan

12.7.2. Market Size of Chronic Pulmonary Hypertension by Therapies in Japan

13. KOL Views

14. SWOT Analysis

16. Appendix

16.1. Bibliography

16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Table

Table 1: Summary of Chronic Pulmonary Hypertension, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Treatment options for pulmonary hypertension by WHO classification

Table 3: Total number of Prevalent Cases of Chronic Pulmonary Hypertension in the 7MM (2019–2032)

Table 4: Total prevalent cases of Chronic Pulmonary Hypertension in the US (2019–2032)

Table 5: Group-specific Prevalence of Chronic Pulmonary Hypertension in the United States in 000’s (2019–2032)

Table 6: Gender-specific Prevalence of Chronic Pulmonary Hypertension in the United States (2019–2032)

Table 7: Age-specific prevalent cases of Chronic Pulmonary Hypertension in the United States (2019–2032)

Table 8: Total prevalent cases of Chronic Pulmonary Hypertension in the EU5 (2019–2032)

Table 9: Group-specific Prevalence of Chronic Pulmonary Hypertension in the EU5 in 000’s (2019–2032)

Table 10: Gender-specific prevalent cases of Chronic Pulmonary Hypertension in the EU5 (2019–2032)

Table 11: Age-specific prevalent cases of Chronic Pulmonary Hypertension in the United States (2019–2032)

Table 12: Total prevalent cases of Chronic Pulmonary Hypertension in Japan (2019–2032)

Table 13: Group-specific Prevalence of Chronic Pulmonary Hypertension in Japan in 000’s (2019–2032)

Table 14: Gender-specific Prevalence of Chronic Pulmonary Hypertension in Japan (2019–2032)

Table 15: Age-specific prevalent cases of Chronic Pulmonary Hypertension in Japan (2019–2032)

Table 16: CS1, Clinical Trial Description, 2022

Table 17: Zamicastat, Clinical Trial Description, 2022

Table 18: YUTREPIA (LIQ861 Inhaled Treprostinil), Clinical Trial Description, 2022

Table 19: INO pulse A, Clinical Trials, 2022

Table 20: Levosimendan, Clinical Trials 2022

Table 21: Market size of Chronic Pulmonary Hypertension in the 7MM, in USD million (2019–2032)

Table 22: Market size of Chronic Pulmonary Hypertension by therapies in the 7MM, in USD million (2019–2032)

Table 23: Market size of Chronic Pulmonary Hypertension in the United States, USD million (2019–2032)

Table 24: Market size of Chronic Pulmonary Hypertension by therapies in the US, in USD million (2019–2032)

Table 25: Market size of Chronic Pulmonary Hypertension in the EU5, in USD million (2019–2032)

Table 26: Market size of Chronic Pulmonary Hypertension by therapies in the EU5, in USD million (2019–2032)

Table 27: Market Size of Chronic Pulmonary Hypertension pain in Japan, in USD million (2019–2032)

Table 28: Market size of Chronic Pulmonary Hypertension by therapies in Japan, in USD million (2019–2032)

List of Figures

Figure 1: Vascular architecture in pulmonary hypertension. Cross-sectional representation of a normal pulmonary arteriole and a pulmonary arteriole in pulmonary hypertension

Figure 2: Pulmonary hypertension is classified into five distinct groups based on the findings and recommendations from world experts at the most recent World Symposium on Pulmonary Hypertension

Figure 3: Schematic representations of pulmonary hypertension. Representation of site of initiation of elevated pulmonary arterial pressure of pre capillary pulmonary hypertension, post-capillary pulmonary hypertension, and CTEPH. L.V., left ventricle; PH, pulmonary hypertension; R.A., right atrium; R.V., right ventricle.

Figure 4: Pathophysiological mechanisms of PAH. Environmental insults can contribute to PAEC damage and injury. In the healthy state, physiological repair processes restore normal lung function via proliferation of nearby ECs and/or the recruitment of circulating endothelial progenitor cells (EPCs). In PAH, pulmonary vascular cell damage contributes to the degeneration of microvasculature and/or arteriolar remodeling. In patients with hereditary PAH underlying genetic mutations are associated with increased susceptibility to PAEC damage and injury

Figure 5: Total number of Prevalent cases of Chronic Pulmonary Hypertension in the 7MM (2019–2032)

Figure 6: Total prevalent cases of Chronic Pulmonary Hypertension in the US (2019–2032)

Figure 7: Group-specific Prevalence of Chronic Pulmonary Hypertension in the United States in 000’s (2019–2032)

Figure 8: Gender-specific Prevalence of Chronic Pulmonary Hypertension in the United States (2019–2032)

Figure 9: Age-specific prevalent cases of Chronic Pulmonary Hypertension in the United States (2019–2032)

Figure 10: Total prevalent cases of Chronic Pulmonary Hypertension in the EU5 (2019–2032)

Figure 11: Group-specific Prevalence of Chronic Pulmonary Hypertension in EU5 in 000’s (2019–2032)

Figure 12: Gender-specific prevalent cases of Chronic Pulmonary Hypertension in the EU5 (2019–2032)

Figure 13: Age-specific prevalent cases of Chronic Pulmonary Hypertension in the EU5 (2019–2032)

Figure 14: Total prevalent cases of Chronic Pulmonary Hypertension in Japan (2019–2032)

Figure 15: Group-specific Prevalence of Chronic Pulmonary Hypertension in Japan in 000’s (2019–2032)

Figure 16: Gender-specific Prevalence of Chronic Pulmonary Hypertension in Japan (2019–2032)

Figure 17: Age-specific prevalent cases of Chronic Pulmonary Hypertension in Japan (2019–2032)

Figure 18: Market size of Chronic Pulmonary Hypertension in the 7MM, in USD million (2019–2032)

Figure 19: Market size of Chronic Pulmonary Hypertension by therapies in the 7MM, in USD million (2019–2032)

Figure 20: Market size of Chronic Pulmonary Hypertension in the United States, USD millions (2019–2032)

Figure 21: Market size of Chronic Pulmonary Hypertension by therapies in the US, in USD million (2019–2032)

Figure 22: Market size of Chronic Pulmonary Hypertension in the EU-5, USD million (2019–2032)

Figure 23: Market size of Chronic Pulmonary Hypertension by therapies in EU-5, in USD million (2019–2032)

Figure 24: Market Size of Chronic Pulmonary Hypertension in Japan, USD million (2019–2032)

Figure 25: Market size of Chronic Pulmonary Hypertension by therapies in Japan, in USD million (2019–2032)

Bayer
Attgeno AB
Cereno Scientific AB
Bial - Portela C S.A
Liquidia Technologies
Bellerophon Therapeutics
AbbVie/Tenax Therapeutics
Insmed
Altavant Sciences

 

Forward to Friend

Need A Quote